Neos Therapeutics: Q3 Earnings Insights

Shares of Neos Therapeutics NEOS were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share fell 150.00% over the past year to ($0.10), which missed the estimate of ($0.05).

Revenue of $12,535,000 decreased by 28.53% from the same period last year, which missed the estimate of $15,470,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Neos Therapeutics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/svva5soo

Technicals

Company's 52-week high was at $1.98

Company's 52-week low was at $0.45

Price action over last quarter: Up 2.22%

Company Profile

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.